BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of B-cell leukemia or lymphoma of 1 of the following types:
• * Chronic lymphocytic leukemia
• * Failed standard chemotherapy
• * Prolymphocytic leukemia
• * Failed standard chemotherapy
• * Indolent non-Hodgkin's lymphoma, including mantle cell lymphoma
• * Stage III or IV disease
• * Failed ≥ 1 prior doxorubicin- or fludarabine-containing standard therapy
• CD22-positive disease, as evidenced by 1 of the following:
• * More than 15% malignant cells react with anti-CD22 by immunohistochemistry
• * More than 30% malignant cells are CD22-positive by fluorescence-activated cell sorting analysis
• * More than 400 CD22 sites per malignant cell (average) by radiolabeled anti-CD22 binding
• Treatment is medically indicated, as evidenced by any of the following:
• * Progressive disease-related symptoms
• * Progressive cytopenias due to marrow involvement
• * Progressive or painful splenomegaly or adenopathy
• * Rapidly increasing lymphocytosis
• * Autoimmune hemolytic anemia or thrombocytopenia
• * Increased frequency of infections
• No neutralizing anti-toxin or anti-mouse immunoglobulin G (IgG) antibodies to BL22 or PE38
• * No serum neutralization of \> 75% of the activity of 1 μg/mL of BL22
• No CNS disease requiring treatment
• No hairy cell leukemia
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• More than 6 months
• Hematopoietic
• Absolute neutrophil count \> 1,000/mm\^3\*
• Platelet count \> 40,000/mm\^3 NOTE: \*Patients with leukemia are eligible regardless of absolute neutrophil count; Grade III-IV pancytopenia or growth factor dependence allowed if due to disease
• Hepatic
• Bilirubin \< 1.5 times upper limit of normal (ULN)
• ALT and AST \< 2.5 times ULN
• Renal
• Creatinine ≤ 1.5 mg/dL
• Pulmonary
• FEV1 ≥ 60% of predicted
• DLCO ≥ 55% of predicted
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Prior bone marrow transplantation allowed
• More than 3 weeks since prior biologic therapy, including interferon, denileukin diftitox, or LMB-2 immunotoxin
• More than 3 months since prior monoclonal antibody therapy (e.g., rituximab)
• Chemotherapy
• See Disease Characteristics
• More than 3 weeks since prior cytotoxic chemotherapy
• Endocrine therapy
• More than 1 week since prior steriods
• * Less than 5 doses for non-treatment reasons (e.g., allergy prophylaxis)
• * No evidence of disease response
• Radiotherapy
• More than 3 weeks since prior whole-body electron beam radiotherapy
• * Radiotherapy within the past 3 weeks allowed provided the volume of bone marrow treated is \< 10% AND the patient has measurable disease located outside the radiation port
• Surgery
• Not specified
• Other
• More than 3 weeks since prior retinoids
• More than 3 weeks since other prior systemic therapy for this malignancy